PT - JOURNAL ARTICLE AU - AKIKO SHIMAZAKI AU - MAKOTO KUBO AU - KANAKO KURATA AU - YUKA TAKAO AU - SAORI HAYASHI AU - YURINA HARADA AU - HITOMI KAWAJI AU - KAZUHISA KANESHIRO AU - MAI YAMADA AU - MASAYA KAI AU - MASAFUMI NAKAMURA TI - CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients AID - 10.21873/anticanres.15904 DP - 2022 Aug 01 TA - Anticancer Research PG - 4071--4077 VI - 42 IP - 8 4099 - http://ar.iiarjournals.org/content/42/8/4071.short 4100 - http://ar.iiarjournals.org/content/42/8/4071.full SO - Anticancer Res2022 Aug 01; 42 AB - Background/Aim: Abnormalities in the cyclin D1–CDK4/6 complex have been implicated in breast cancer proliferation and resistance to treatment. Recently, new drugs have been developed to target CDK4/6. Meanwhile, liquid biopsy has received great interest in oncology. In this study, we analyzed cyclin D1 gene (CCND1) copy number variation (CNV) in circulating tumor DNA (ctDNA) from luminal B breast cancer patients. Patients and Methods: This study included 31 patients with luminal B breast cancer who underwent resection. We analyzed CCND1 CNV in ctDNA by digital droplet PCR. Results: Of the 31 luminal B breast cancers, CCND1 CNV was positive in 5 cases. Patients with CCND1 CNV positivity had significantly shorter recurrence-free survival than patients with negative CCND1 CNV. Conclusion: CCND1 CNV in ctDNA was associated with poor prognosis in patients with luminal B breast cancer. This biomarker could be a useful prognostic factor.